查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615410

吉米沙星市场：按形式、适应症和销售管道- 全球预测 2025-2030

Gemifloxacin Market by Form (Solution, Tablet), Indication (Respiratory Infection, Urinary Tract Infection), Sales Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年吉米沙星市值为7.0559亿美元，预计2024年将达到7.4101亿美元，复合年增长率为4.88%，预计到2030年将达到9.8509亿美元。

吉米沙星是一种Fluoroquinolones抗生素，主要用于治疗细菌感染疾病，特别是呼吸道感染疾病，如肺炎、支气管炎和鼻窦炎。它们的范围和效用取决于它们对其他抗生素抗药性的革兰氏阴性和革兰氏阳性病原体的有效性。因此，在传统抗生素无效的情况下，需要吉米沙星作为先进的治疗选择。吉米沙星的应用涵盖製药和医疗领域，特别是在医院和门诊诊所。最终用途包括直接配製和纳入更广泛的抗菌治疗制度。市场洞察表明，由于呼吸道疾病的增加以及对抗多重抗药性细菌的兴趣日益浓厚，预计将出现强劲增长。随着非专利市场因专利到期扩大，拥有先进医疗基础设施的新兴经济体的商机已经成熟。专注于优化递送机制的研究投资，例如缓释性和联合治疗，为业务成长提供了肥沃的土壤。然而，严格的法律规范和与Fluoroquinolones抗生素相关的潜在副作用等限制限制了其在某些地区的使用。抗药性细菌的发展以及来自大环内酯类和Ketolide等替代疗法的竞争给市场扩张带来了进一步的挑战。创新者可以利用对病原体抗药性的遗传见解来开发个人化医疗方法，以最大限度地提高吉米沙星的有效性。此外，市场动态揭示了更环保、更永续的製造流程的趋势，为企业领导者提供了将绿色技术融入生产的机会，以吸引环保意识的相关人员。总体而言，驾驭这个市场需要将合规性、创新研究和对人口健康趋势的敏锐洞察进行策略结合。随着呼吸系统疾病盛行率的不断上升，特别是在人口老化中，扩展到服务不足的地区可以带来显着的好处。采取此类措施将有助于维持市场相关性并应对消费者期望和监管环境的变化。

主要市场统计
基准年[2023] 70559万美元
预计年份 [2024] 74101万美元
预测年份 [2030] 98509万美元
复合年增长率（%） 4.88%

市场动态：揭示快速发展的吉米沙星市场的关键市场洞察

供需的动态交互作用正在改变吉米沙星市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于其广泛的抗菌特性，对吉米沙星的需求不断增加
    • 支持医疗基础设施改革以改善抗生素的获取
  • 市场限制因素
    • 因安全问题而召回产品
  • 市场机会
    • 吉米沙星生产技术不断进步
    • 製药公司与学术/研究机构之间的伙伴关係
  • 市场问题
    • 仿冒品盛行及生产问题

波特五力：驾驭吉米沙星市场的策略工具

波特五力：框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解吉米沙星市场的外部影响

外部宏观环境因素在塑造吉米沙星市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解吉米沙星市场的竞争格局

对吉米沙星市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：吉米沙星市场供应商的绩效评估

FPNV定位矩阵是评估吉米沙星市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製吉米沙星市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对吉米沙星市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 广谱抗菌特性增加了对吉米沙星的需求
      • 对卫生基础设施进行支持性改革，以增加抗生素的获取
    • 抑制因素
      • 因安全问题而召回产品
    • 机会
      • 吉米沙星生产技术不断进步
      • 製药公司与学术或研究机构之间的合作关係
    • 任务
      • 仿冒品的盛行与製造问题
  • 市场区隔分析
    • 形式：吉米沙星锭剂因其方便常规门诊病人使用而越来越受欢迎
    • 分销管道：根据医疗专业人员的诊断和处方，透过医院药房扩大吉米沙星的获取范围
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 吉米沙星市场：依形式

  • 介绍
  • 解决方案
  • 锭剂

第七章 吉米沙星市场：依适应症分类

  • 介绍
  • 呼吸道感染疾病
  • 尿道感染

第八章 吉米沙星市场：按分销管道

  • 介绍
  • 医院药房
  • 网路商店
  • 零售药房

第九章 美洲吉米沙星市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太吉米沙星市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲吉米沙星市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Sun Pharma 与太郎製药签署收购协议
  • 战略分析和建议

公司名单

  • Alkem Laboratories Ltd.
  • Aurobindo Pharma Limited
  • BASF SE
  • Emcure Pharmaceuticals Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Mylan NV
  • Orchid Chemicals & Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-5D693B46C82C

The Gemifloxacin Market was valued at USD 705.59 million in 2023, expected to reach USD 741.01 million in 2024, and is projected to grow at a CAGR of 4.88%, to USD 985.09 million by 2030.

Gemifloxacin is a fluoroquinolone antibiotic primarily used to treat bacterial infections, specifically respiratory tract infections like pneumonia, bronchitis, and sinusitis. Its scope and utility are defined by its efficacy in combating Gram-negative and Gram-positive pathogens resistant to other antibiotics. This creates a necessity for gemifloxacin as an advanced treatment option in settings where traditional antibiotics fail. Its applications span both pharmaceutical and healthcare sectors, particularly within hospitals and outpatient clinics. End-use includes direct prescriptions and integration into broader antimicrobial treatment regimes. Market insights indicate a robust growth trajectory driven by increasing respiratory ailment cases and a heightened focus on multi-drug resistance management. Opportunities are ripe in emerging economies where healthcare infrastructure development is on the rise, alongside expanding generic markets due to patent expirations. Research investments focusing on optimizing delivery mechanisms, such as slow-release formulations and combination therapies, represent fertile ground for business growth. However, limitations include stringent regulatory frameworks and potential adverse effects associated with fluoroquinolones, which have led to restricted use in several regions. Resistance development and competition from alternative therapeutics, like macrolides and ketolides, further challenge market expansion. Innovators could leverage genetic insights into pathogen resistance and develop personalized medicine approaches to maximize gemifloxacin's effectiveness. Additionally, market dynamics reveal a trend towards eco-friendly and sustainable manufacturing processes, presenting opportunities for business leaders to incorporate green technologies into production, thereby appealing to environmentally conscious stakeholders. Overall, navigating this market demands a strategic blend of compliance adherence, innovative research, and a keen eye on demographic health trends. With the growing incidence of respiratory diseases, particularly in aging populations, a calculated expansion into underserved regions could yield substantial returns. Adopting these measures can ensure sustained market relevance and capitalize on evolving consumer expectations and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 705.59 million
Estimated Year [2024] USD 741.01 million
Forecast Year [2030] USD 985.09 million
CAGR (%) 4.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gemifloxacin Market

The Gemifloxacin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
    • Supportive reforms in healthcare infrastructure enhancing access to antibiotics
  • Market Restraints
    • Product recalls due to safety concerns
  • Market Opportunities
    • Continuous advancements in production technologies of gemifloxacin
    • Partnerships between pharmaceutical companies and academic or research institutions
  • Market Challenges
    • Prevalence of counterfeit products and production issues

Porter's Five Forces: A Strategic Tool for Navigating the Gemifloxacin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gemifloxacin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gemifloxacin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gemifloxacin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gemifloxacin Market

A detailed market share analysis in the Gemifloxacin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gemifloxacin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gemifloxacin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gemifloxacin Market

A strategic analysis of the Gemifloxacin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gemifloxacin Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Aurobindo Pharma Limited, BASF SE, Emcure Pharmaceuticals Ltd., Hanmi Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Mylan N.V., Orchid Chemicals & Pharmaceuticals Ltd., Pfizer Inc., Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Gemifloxacin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Form, market is studied across Solution and Tablet.
  • Based on Indication, market is studied across Respiratory Infection and Urinary Tract Infection.
  • Based on Sales Channel, market is studied across Hospital Pharmacy, Online Stores, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for gemifloxacin due to broad-spectrum antibacterial properties
      • 5.1.1.2. Supportive reforms in healthcare infrastructure enhancing access to antibiotics
    • 5.1.2. Restraints
      • 5.1.2.1. Product recalls due to safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous advancements in production technologies of gemifloxacin
      • 5.1.3.2. Partnerships between pharmaceutical companies and academic or research institutions
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of counterfeit products and production issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Form: Growing availability of tablet form of gemifloxacin as it is convenient for regular outpatient use
    • 5.2.2. Sales Channel: Growing accessibility of gemifloxacin through hospital pharmacies following a diagnosis and prescription from a healthcare professional
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gemifloxacin Market, by Form

  • 6.1. Introduction
  • 6.2. Solution
  • 6.3. Tablet

7. Gemifloxacin Market, by Indication

  • 7.1. Introduction
  • 7.2. Respiratory Infection
  • 7.3. Urinary Tract Infection

8. Gemifloxacin Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Stores
  • 8.4. Retail Pharmacy

9. Americas Gemifloxacin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gemifloxacin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gemifloxacin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Sun Pharma Finalizes Acquisition Agreement with Taro Pharmaceutical
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Aurobindo Pharma Limited
  • 3. BASF SE
  • 4. Emcure Pharmaceuticals Ltd.
  • 5. Hanmi Pharmaceutical Co., Ltd.
  • 6. Hikma Pharmaceuticals PLC
  • 7. Mylan N.V.
  • 8. Orchid Chemicals & Pharmaceuticals Ltd.
  • 9. Pfizer Inc.
  • 10. Stada Arzneimittel AG
  • 11. Sun Pharmaceutical Industries Ltd.
  • 12. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GEMIFLOXACIN MARKET RESEARCH PROCESS
  • FIGURE 2. GEMIFLOXACIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GEMIFLOXACIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GEMIFLOXACIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GEMIFLOXACIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GEMIFLOXACIN MARKET DYNAMICS
  • TABLE 7. GLOBAL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GEMIFLOXACIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GEMIFLOXACIN MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GEMIFLOXACIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GEMIFLOXACIN MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GEMIFLOXACIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GEMIFLOXACIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GEMIFLOXACIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GEMIFLOXACIN MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. GEMIFLOXACIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. GEMIFLOXACIN MARKET, FPNV POSITIONING MATRIX, 2023